Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study

Distinguishing acquired (idiopathic/immune) severe aplastic anemia (SAA) from inherited bone marrow failure syndromes (IBMFS) is critical since only acquired cases respond to immunosuppressive therapy (IST), the standard treatment in cases without a matched sibling donor. Differentiating SAA from IBMFS is particularly challenging in children younger than 3 years, in whom inherited disorders are more prevalent. No age threshold exists to guide IST use in this population. Thus, we evaluated IST outcomes in children aged.

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-04-16
DOI
https://doi.org/10.3324/haematol.2025.300232
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study

Amy E. Geddis, Michaela Cada, Talya Wittmann Dayagi, BE Glader et al.
Haematologica
Hematopoietic Stem Cell Transplantation
article

Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study

Amy E. Geddis, Michaela Cada, Talya Wittmann Dayagi, BE Glader, Christopher Gamper, Zora R. Rogers, Taizo A. Nakano, Staci D. Arnold, Yigal Dror, D A Williams, Thomas D. Coates, Gary M. Kupfer, Jessica Boklan, Catherine Corriveau-Bourque, Timothy S. Olson, Clifford Takemoto, Akiko Shimamura, Laura Willis, Alexis A. Thompson
article en

Abstract

Distinguishing acquired (idiopathic/immune) severe aplastic anemia (SAA) from inherited bone marrow failure syndromes (IBMFS) is critical since only acquired cases respond to immunosuppressive therapy (IST), the standard treatment in cases without a matched sibling donor. Differentiating SAA from IBMFS is particularly challenging in children younger than 3 years, in whom inherited disorders are more prevalent. No age threshold exists to guide IST use in this population. Thus, we evaluated IST outcomes in children aged.

Haematologica
Seattle Children's Hospital (US), St. Jude Children's Research Hospital (US), Children's Hospital of Philadelphia (US), Children's Hospital of Los Angeles (US), Harvard University (US), University of Arizona (US), Johns Hopkins University (US), Palo Alto University (US), Georgetown University (US), University of Toronto (CA), Georgetown University Medical Center (US), Hospital for Sick Children (CA), Children's Hospital Colorado (US), Center for Cancer and Blood Disorders (US), Children's Healthcare of Atlanta (US), Stollery Children's Hospital (CA), Sidney Kimmel Comprehensive Cancer Center (US), Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US), The University of Texas Southwestern Medical Center (US), University of Colorado Denver (US), Stanford University (US)
Aplastic Anemia and Myelodysplasia Association of Canada
Good health and well-being
Openalex Percentile: Top 20%
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.